natgillin/translations-raw huggingface dataset:
Der blev fundet duloxetin i modermælken.
Duloxetine is detected in breast milk, and steady-state concentrations in breast
Mængden af duloxetin i modermælk er ca.
11 milk are about one-fourth those in plasma.
I et embryotoxicitetstudie foretaget på kaniner blev der observeret en højere incidens af kardiovaskulære - og knogle- deformationer, hvor hunkaninerne blev udsat for systemiske påvirkninger under den maksimale kliniske eksponering (AUC).
In an embryotoxicity study in the rabbit, a higher incidence of cardiovascular and skeletal malformations was observed at systemic exposure levels below the maximun clinical exposure (AUC).
Duloxetin fremkaldte adfærdsmæssige bivirkninger hos afkommet i et præ - / postnatal toxicitetstudie med rotter, hvor hunrotter blev udsat for systemiske påvirkninger under den maksimale kliniske eksponering (AUC).
In pre/ postnatal toxicity study in the rat, duloxetine induced adverse behavioural effects in the offspring at systemic exposures levels below maximum clinical exposure (AUC).
12 Kapselskal:
Capsule shell:
Mat blå kapselbund med påskriften ” 20 mg ” og mat blå kapseltop med påskriften ” 9544 ”.
The capsule has an oOpaque blue body, imprinted with ‘ 20 mg’ and an opaque blue cap, imprinted with ‘ 9544’.
14 Børn og unge:
14 Children and adolescents:
Der bør ligeledes
Duloxetine 15 should be used with caution in patients whose conditions could be compromised by an increased heart rate or by an increase in blood pressure.
15 udvises forsigtighed, når duloxetin bruges sammen med lægemidler, der kan forringe dets metabolisme (se pkt.
Caution should also be exercised when duloxetine is used with medicinal products that may impair its metabolism (see section 4.5).
YENTREVE og placebo.
In a clinical trial, adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
Patienter, der tidligere har udført selv - mordsrelaterede handlinger, eller patienter, der før behandlingsstart har udvist en signifikant grad af selvmordsforestillinger, har en større risiko for selvmordstanker eller selvmordsadfærd og bør følges nøje under behandlingen.
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at a greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment.
En metaanalyse af placebokontrollerede kliniske forsøg af antidepressive lægemidler til behandling af psykiske lidelser viste en forøget risiko for selvmordsadfærd med anti - depressiva sammenlignet med placebo hos patienter under 25 år.
A meta-analysis of placebo- controlled clinical trials of antidepressants medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old Cases of suicidal thoughts and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.8).
Der er blevet rapporteret tilfælde af selvmordstanker og - adfærd under duloxetinbehandling eller tidligt efter behandlingens ophør (se pkt.
Physicians should encourage patients to report any distressing thoughts or feelings or depressive symptoms at any time.
Læger bør opfordre patienterne til at rapportere, hvis de
If while on YENTREVE therapy, the patient develops agitation or depressive symptoms, specialised medical advice should be sought, as depression is a serious medical condition.
Hvis patienten under behandling med YENTREVE udvikler agitation eller depressive symptomer bør en specialist konsulteres, eftersom depression er en alvorlig medicinsk tilstand.
If a decision to initiate antidepressant 16 pharmacological therapy is taken, the gradual discontinuation of YENTREVE is recommended (see Section 4.2).
Det anbefales at udvise forsigtighed, når YENTREVE tages sammen med andre centralt virkende lægemidler eller stoffer, herunder alkohol og sederende lægemidler (benzodiazepiner, morfinlignende præparater, antipsykotika, phenobarbital, sederende antihistaminer).
CNS medicinal products: caution is advised when YENTREVE is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
17 Duloxetins virkning på andre lægemidler Lægemidler, der metaboliseres via CYP1A2:
Effect of duloxetine on other medicinal products Medicinal products metabolised by CYP1A2:
Samtidig behandling med duloxetin (40 mg to gange daglig) forøger steady state- AUC for tolterodin (2 mg to gange daglig) med 71%, men påvirker ikke farmakokinetikken for tolterodins aktive 5- hydroxy- metabolit, og der anbefales ingen dosisjustering.
The co-administration of duloxetine (40 17 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71%, but does not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended.
Tabel 1 viser observerede bivirkninger fra spontane rapporter samt fra placebo- kontrollerede kliniske forsøg med SUI og andre lidelser i de nedre urinveje (omfattende en total på 7976 patienter - heraf fik 4370 patienter duloxetin og 3606 patienter fik placebo).
18 Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 7977 patients, 4371 on duloxetine and 3606 on placebo) in SUI and other lower urinary tract disorders.
De mest almindelige rapporterede bivirkninger hos patienter i behandling med YENTREVE i kliniske forsøg med SUI og andre lidelser i de nedre urinveje var kvalme, mundtørhed, træthed og forstoppelse.
The most commonly reported adverse events in patients treated with YENTREVE in clinical trials in SUI and other lower urinary tract disorders were nausea, dry mouthand fatigue -.
Meget almindelige (≥1/ 10), almindelige (≥1/ 100 til, < 1/ 10), ikke almindelig (≥1/ 1. 000 til, < 1/ 100), sjælden (≥1/ 10. 000 til, < 1/ 1. 000), meget sjælden (< 1/ 10. 000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Very common (≥ 1/ 10), common (≥ 1/ 100 to < 1/ 10), uncommon (≥ 1/ 1,000 to < 1/ 100), rare (≥ 1/ 10,000 and < 1/ 1,000), very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
hyppighed
Cardiac Disorders
Undersøgelser Hjerte
Weight decrease Weight increase Blood cholesterol increased
Vægttab Vægtstigning Øget blodkolesterol
Creatine phosphokinase increased
Kreatininkinase øget
Palpitations Nervous System Disorders
Nervesystemet
Tachycardia
Palpitationer
Supra- ventricular arrhythmia, mainly atrial fibrillation
Takykardi
Headache Dizziness Tremor Lethargy Somnolence Paraesthesia Eye Disorders
Supra - ventrikulær arytmi, hovedsagelig atrieflimren
Poor quality sleep Disturbance in attention Nervousness Dysgeusia
Øjne
Dyskinesia Myoclonus
Hovedpine Svimmelhed Rysten Letargi Søvnighed Paræstesier
Serotonin syndrome Psychomotor restlessness Convulsions Akathisia Extrapyramidal symptoms
Dårlig søvnkvalitet Koncentrations - besvær Nervøsitet Dysgeusi
Blurred vision Ear and Labyrinth Disorders
Dyskinesi Myoclonus
Tinnitus1 Ear pain
Serotoninsyn - drom Psykomotorisk uro Kramper Akatisi Ekstrapyrami - dale symptomer
Respiratory, thoracic and mediastinal disorders Gastrointestinal Disorders
Ører og labyrint
Yawning
Sløret syn
Epistaxis Throat tightness
Synsforstyrrelser Mydriasis
Gastroenteritis Stomatitis Gastritis
Glaukom
Haematochezia
Vertigo
Very Rare
Tinnitus 1 Ørepine
Frequency not known
sjælden
(11.9%) Constipation (10.3%) Renals and Urinary Disorders
hyppighed
Flatulence Eructation Breath odour
Luftveje, thorax og mediastinum Mave- tarmkanalen
Urinary hesitation Dysuria Nocturia Urine odour abnormal
Gaben
Urine flow decreased Polyuria
Epistaxis Sammensnøret hals
Urinary retention
Kvalme (23, 3%) Mundtørhed (11, 9%) Forstoppelse (10, 3% Nyrer og urinveje
Skin and Subcutaneous Tissue Disorders
Diarré Opkastning Dyspepsi
Sweating increased
Gastroenteritis Stomatitis Gastritis Flatulens Opstød Dårlig ånde
Rash Increased tendency to bruise Night sweats Cold sweat
Frisk blødning per rectum
Photo- sensitivity reactions Dermatitis contact Urticaria
Gastrointestinal blødning
Stevens- Johnson Syndrome Angioneurotic oedema
Urinretention Besværet vandladning Dysuri Natlig vandladning
Muscoskeletal and connective tissue disorders Endocrine disorders Metabolism and Nutrition Disorders
Nedsat urinmængde Polyuri
Muscle spasm Muscle tightness Musculo- skeletal pain Trismus Hypo- thyroidism
Abnorm urinlugt
Muscle twitching
Hud og subkutane væv
Appetite decreased Infections and infestations
Øget perspira - tion
Dehydration
Hududslæt Øget tendens til at få blå mærker Nattesved Koldsved
Hyperglycemia (reported especially in diabetic patients) SIADH Hyponatremia
Lysfølsomheds reaktioner Kontaktderma - titis Nældefeber
Laryngitis Vascular Disorders
Stevens - Johnson syndrom Angioneurotisk ødem
Flushing
Knogler, led, muskler og bindevæv Det endokrine system Metabolisme og ernæring
Syncope2 Blood pressure increase
Muskelkramper Muskelstivhed Musculoskeletale smerter Trismus Hypotyroidisme
Hypertensive crisis Orthostatic hypotension2Pe ripheral coldness
Muskelsitren
Hypertension
Nedsat appetit Infektioner og parasitære sygdomme Vaskulære sygdomme
General Disorders and Administration Site Conditions Fatigue (10.9%)
Dehydrering Laryngitis
Abdominal pain Pruritus Weakness Chills
Hyperglykæmi (især rapporteret hos diabetikere) SIADH Hyponatriæmi
Malaise Feeling abnormal Feeling hot Thirst
Synkope2 Blodtryksfor - øgelse
Gait disturbance Feeling cold
Hypertension
Chest pain
Almene symptomer og reaktioner på administrationsstedet Træthed
Immune system disorders
Mavesmerter
Hyper- sensitivity
Generel
Anaphylactic reaction
20
20 Very common
Desorientering Abnorme drømme Apati Tænderskæren Abnorm orgasme
Disorientation Hallucinations Abnormal dreams Apathy Bruxism Orgasm abnormal
HbA1C var stabilt hos både duloxetin- behandlede og placebo- behandlede patienter.
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine- treated patients.
21 Extension- fasen af disse forsøg varede op til 52 uger.
HbA1c was stable in both duloxetine-treated and placebo-treated patients.
22 Virkningen af YENTREVE er ikke blevet undersøgt længere end 3 måneder i placebokontrollerede studier.
The efficacy of YENTREVE has not been evaluated for longer than 3 months in placebo-controlled studies.
Resultater fra livskvalitets - / Incontinence Quality of Life (I- QOL) undersøgelser viste sig signifikant forbedret i gruppen med duloxetin- behandlede patienter sammenlignet med placebo - gruppen (9, 2 mod 5, 9 i score forbedring, p < 0, 001).
Using a global improvement scale (PGI), significantly more women
Ved brug af en Patient Global Improvement (PGI) skala viste kvinder behandlet med duloxetin at vurdere deres symptomer på stressinkontinens som signifikant forbedret i forhold til kvinder på placebo (64, 6% mod 50, 1%, p < 0, 001).
22 using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p < .001).
Der er begrænset data som tyder på, at fordelene ved YENTREVE ikke mindskes hos kvinder med stressinkontinens, som tidligere er blevet opereret for inkontinens.
YENTREVE and Prior Continence Surgery: there are limited data that suggest that the benefits of YENTREVE are not diminished in women with stress urinary incontinence who have previously undergone continence surgery.
Ammende mødre:
23 Nursing mothers:
24 Kapselskal:
Capsule shell:
FREMSTILLER( E) ANSVARLIG( E) FOR BATCHFRIGIVELSE
26 A MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Lilly SA Avenida de la Industria No 30 28108 Alcobendas Madrid Spanien
Lilly SA Avenida de la Industria No 30 28108 Alcobendas Madrid Spain
YENTREVE 40 mg hårde enterokapsler Duloxetin
YENTREVE 40 mg, hard gastro-resistant capsules.
28 hårde enterokapsler 56 hårde enterokapsler 98 hårde enterokapsler 140 hårde enterokapsler
packs of 28 hard gastro-resistant capsules 56 hard gastro-resistant capsules 98 hard gastro-resistant capsules 140 hard gastro-resistant capsules
EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF UBRUGTE LÆGEMIDLER ELLER AFFALD FRA SÅDANNE
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 30 OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
ETIKET TIL MULTIPAKNING (2X98 KAPSLER, 40 MG) OMVIKLET MED PLASTFOLIE (MED BLUE BOX)
33 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER WRAPPER LABEL ON MULTIPACKS (2X98 CAPSULES, 40 MG) WRAPPED IN FOIL (INCLUDING BLUE BOX)
(40 MG HÅRDE ENTEROKAPSLER)
35 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS (40 mg hard gastro- resistant capsules)
YENTREVE 20 mg hårde enterokapsler Duloxetin
YENTREVE 20 mg, hard gastro-resistant capsules.
28 hårde enterokapsler 56 hårde enterokapsler 98 hårde enterokapsler
Packs of 28 hard gastro-resistant capsules Packs of 56 hard gastro-resistant capsules Packs of 98 hard gastro-resistant capsules.
(20 MG HÅRDE ENTEROKAPSLER)
38 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS (20 mg hard gastro- resistant capsules)
YENTREVE 40 mg hårde enterokapsler YENTREVE 20 mg hårde enterokapsler Duloxetin (som hydrochlorid)
YENTREVE 40 mg hard gastro resistant capsules YENTREVE 20 mg hard gastro resistant capsules Duloxetine (as hydrochloride)
- Lægen har ordineret YENTREVE til Dem personligt.
- This medicine has been prescribed for you.
YENTREVEs virkning og hvad De skal bruge det til 2.
What YENTREVE is and what it is used for 2.
Det skal De vide, før De begynder at tage YENTREVE 3.
Before you take YENTREVE 3.
Sådan skal De tage YENTREVE 4.
How to take YENTREVE 4.
Bivirkninger 5 Sådan opbevarer De YENTREVE 6.
How to store YENTREVE 6.
YENTREVES VIRKNING OG HVAD DE SKAL BRUGE DET TIL
WHAT YENTREVE IS AND WHAT IT IS USED FOR
YENTREVE øger niveauerne af serotonin og noradrenalin i nervesystemet.
YENTREVE increases the levels of serotonin and norepinephrine in the nervous system.
YENTREVE menes at virke ved at øge styrken i lukkemusklen i blæren, som holder urinen tilbage, når du ler, nyser eller udøver fysisk aktivitet.
YENTREVE is believed to work by increasing the strength of the muscle that holds back urine when you laugh, sneeze, or perform physical activities.
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE YENTREVE
BEFORE YOU TAKE YENTREVE
Tag ikke YENTREVE:
Do not take YENTREVE
- hvis De er overfølsom (allergisk) over for duloxetin eller et eller flere af de øvrige
- If you are allergic (hypersensitive) to duloxetine or any of the inactive ingredients of
indholdsstoffer i YENTREVE.
YENTREVE.
- hvis De tager, eller inden for de sidste 14 dage har været i behandling med, en MAO- hæmmer
- If you are taking or have taken within the last 14 days, another medicine known as a monoamine
- hvis De tager fluvoxamin, som normalt anvendes til behandling af depression, ciprofloxacin eller
- If you are taking fluvoxamine which is usually used to treat depression, ciprofloxacin or
enoxacin, som bruges mod infektioner.
enoxacine which are used to treat some infections.
- hvis De har svært nedsat nyrefunktion.
- If you have severe kidney disease.
- hvis De lider af ukontrolleret forhøjet blodtryk.
- If you suffer from uncontrolled high blood pressure.
- hvis De tager medicin imod depression.
- You are taking medicines to treat depression.
- hvis De tager et naturlægemiddel, som indeholder prikbladet perikum (Hypericum perforatum).
John’ s Wort (Hypericum perforatum).
- hvis De har en nyresygdom.
- You have kidney disease.
- hvis De tidligere har lidt af krampeanfald.
- You have a history of seizures (fits).
- hvis De tidligere har lidt af mani eller bipolar lidelse.
- You have a history of mania or bipolar disorder.
- hvis De har øjenproblemer såsom visse typer af grøn stær (glaukom - forøget tryk i øjet).
- You have eye problems such as certain kinds of glaucoma (increased pressure in the eye).
- hvis De tidligere har lidt af blødningsforstyrrelser (tendens til blå mærker).
- You have a history of bleeding disorders (tendency to develop bruises).
- hvis De er under 18 år.
- You are younger than 18 years.
- hvis De har højt blodtryk.
- You have high blood pressure.
- hvis De er i samtidig behandling med medicin, som kan skade leveren.
- You are currently being treated with another medicine which may cause liver damage.
- hvis De samtidig tager anden medicin med duloxetin.
- You are taking other medicines containing duloxetine.
- hvis De ikke tåler visse sukkerstoffer (se nedenunder).
- You have intolerance to some sugars (see below).
3).
- You are considering stopping YENTREVE (see section 3).
Selvmordstanker og forværring af din depression eller angstsygdom Hvis De har en depression eller lider af en angstsygdom, kan De af og til få tanker om at skade dig selv eller begå selvmord.
Thoughts of suicide and worsening of your depression or anxiety disorderIf you are depressed and/ or have anxiety disorders you can sometimes have thoughts of harming or killing yourself.
De vil mere sandsynligt tænke på dette:
You may be more likely to think like this:
- Hvis De tidligere har haft tanker omat begå selvmord eller at skade Dem selv.
- If you have previously had thoughts about killing or harming yourself.
- Hvis De er en yngre person, eftersom erfaringer fra undersøgelser har vist, at der er øget risiko for
Information from clinical trials has shown an increased risk of suicidal
Brug hos børn og unge under 18 år YENTREVE bør ikke bruges til behandling af børn og unge under 18 år.
Use in children and adolescents under 18 years of age YENTREVE should not be used for children and adolescents under the age of 18 years.
Der foreligger endnu ikke data på langtidssikkerhed hos børn og unge hvad angår vækst, modning, kognitiv - og adfærdsudvikling ved brug af YENTREVE.
Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of YENTREVE in this age group have not yet been demonstrated.
Det aktive stof (duloxetin) i YENTREVE bruges i andre lægemidler mod andre tilstande (diabetisk neuropatisk smerte, depression og stressinkontinens).
The main ingredient of YENTREVE, duloxetine, is used in other medicines for other conditions (diabetic neuropathic pain, depression and urinary incontinence).
De må ikke tage YENTREVE sammen med en MAO- hæmmer eller inden for 14 dage efter afsluttet behandling med en MAO- hæmmer.
42 Monoamine Oxidase Inhibitors (MAOI): you should not take YENTREVE with an MAOI or within 14 days of stopping an MAOI.
Hvis De tager en MAO- hæmmer sammen med en række forskellige receptpligtige lægemidler, heriblandt YENTREVE, kan det medføre alvorlige og endda livstruende bivirkninger.
Taking an MAOI together with many prescription medicines, including YENTREVE, can cause serious or even life-threatening side effects.
De skal vente mindst 14
You must wait at least 14 days after you have stopped taking an MAOI before you can take YENTREVE.
42 dage, efter at De er holdt op med at tage en MAO- hæmmer, før De må begynde at tage YENTREVE.
Also, you need to wait at least 5 days after you stop taking YENTREVE before you take an MAOI.
Dette omfatter alkohol og sløvende medicin (benzodiazepiner, morfinlignende præparater, antipsykotika, phenobarbital og sløvende antihistaminer).
CNS medicines: caution is advised when YENTREVE is taken in combination with other centrally acting medicines or substances, including alcohol and sedative medicines (benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines).
Fortæl Deres læge, hvis De tager nogle af disse lægemidler.
Inform your doctor if you are taking any of these medicines.
Følgende er eksempler på disse typer medicin:
Serotonin syndrome: you should tell your doctor if you are taking any of the medicines that act in a similar way to duloxetine.
Oplever De uventede virkninger, mens De tager en af disse typer medicin sammen med YENTREVE, skal De kontakte Deres læge.
These medicines increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with YENTREVE, you should see your doctor.
De bør fortælle Deres læge, hvis De tager orale antikoagulantia (medicin, der fortynder blodet).
You should tell you doctor if you are taking oral – anticoagulants (medicines which thin the blood).
YENTREVE kan tages med og uden mad.
Taking YENTREVE with food and drink YENTREVE may be taken with or without food.
De bør udvise forsigtighed, hvis De drikker alkohol, samtidig med, at De er i behandling med YENTREVE.
You should take extra care if you drink alcohol while taking YENTREVE.
Graviditet Spørg din læge eller apotek til råds, inden De tager nogen form for medicin.
Pregnancy and breast-feeding Tell your doctor if you become pregnant, or you are trying to become pregnant, while you are taking YENTREVE.
Fortæl Deres læge, hvis De bliver gravid, eller hvis De prøver at blive gravid, mens De tager YENTREVE.
You should use YENTREVE only after discussing the potential benefits and any potential risks to your unborn child with your doctor.
De bør kun bruge YENTREVE efter, at De har talt med din læge om de mulige fordele og mulige risici for Deres ufødte barn.
The use of YENTREVE while breastfeeding is not recommended.
Det anbefales ikke at bruge YENTREVE, mens De ammer.
Ask your doctor or pharmacist for advice before taking any medicine.
Trafik - og arbejdssikkerhed YENTREVE kan gøre Dem søvnig og svimmel.
Driving and using machines YENTREVE may make you feel sleepy of dizzy.
YENTREVE indeholder saccharose.
Important information about some of the ingredients of YENTREVE YENTREVE contains sucrose.
SÅDAN SKAL DE TAGE YENTREVE
HOW TO TAKE YENTREVE
Tag altid YENTREVE nøjagtigt efter lægens anvisning.
Always take YENTREVE exactly as your doctor has told you.
Den anbefalede dosis af YENTREVE er én kapsel på 40 mg to gange daglig (om morgenen og sent eftermiddag/ aften).
The recommended dose of YENTREVE is one capsule of 40 mg twice a day (in the morning and late afternoon/ evening).
Deres læge kan beslutte, at De skal starte Deres behandling med én kapsel á 20 mg to gange daglig i to uger før stigning til dosis på 40 mg to gange daglig.
Your doctor may decide to start your treatment with one capsule of 20 mg twice a day for two weeks before increasing the dose to 40 mg twice a day.
43 Stop af behandlingen bør kun ske i samråd med lægen.
43 Do not stop taking YENTREVE without talking to your doctor.
Hvis De har taget for meget YENTREVE Kontakt omgående lægen eller apoteket, hvis De har taget mere YENTREVE, end lægen har ordineret.
If you take more YENTREVE than you should Call your doctor or pharmacist immediately if you take more than the amount of YENTREVE prescribed by your doctor.
Hvis De har glemt at tage YENTREVE De må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
If you forget to take YENTREVE Do not take a double dose to make up for forgotten doses.
Hvis De holder op med at tage YENTREVE:
If you have any further questions on the use of this product, ask your doctor or pharmacist.
De må ikke holde op med at tage kapslerne uden at have konsulteret Deres læge, heller ikke selv om De har fået det bedre.
If you stop taking YENTREVE Do not stop taking your capsules without the advice of your doctor even if you feel better.
Hvis lægen mener, at De ikke længere behøver at tage YENTREVE, vil lægen bede Dem reducere dosis over 2 uger.
If your doctor thinks that you no longer need YENTREVE he will ask you to reduce your dose over 2 weeks.